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Objectives: To assess whether the commercial ViroSeq HIV-1 Genotyping System (Abbott Molecular, Des Plains,
IL, USA) can be used in conjunction with dried blood spots (DBS) for clinical monitoring of drug resistance in
patients who fail antiretroviral treatment (ART) in rural Tanzania.
Patients and methods: Patients at Haydom Lutheran Hospital with conﬁrmed treatment failure (viral load
.1000 copies/mL) of a ﬁrst-line ART regimen were selected for resistance testing. DBS were stored with desic-
cant at 2208C for a median of 126 days (range 0–203) and shipped at ambient temperature for 20 days. After
manual extraction of nucleic acids, the ViroSeq kit was used for ampliﬁcation and sequencing. DBS-derived gen-
otypes were compared with those of a plasma-based assay.
Results: Seventeen of 36 (47%) DBS specimens were successfully genotyped. Only 2 of 16 (13%) DBS with a
viral load ,10000 copies/mL could be ampliﬁed, compared with 15 of 20 (75%) DBS with a viral load
.10000 copies/mL (P¼0.001). In samples that yielded a sequence, all 23 clinically signiﬁcant reverse transcrip-
tase (RT) mutations in plasma were also detected in DBS. One RT mutation was found in DBS only. In the pro-
tease region, 77 polymorphisms were found in plasma, of which 70 (91%) were also detected in DBS. Sixteen of
17 (94%) patients had identical resistance proﬁles to antiretroviral drugs in plasma and DBS.
Conclusions: The ViroSeq kit performed well in patients with a high viral load, but failed to genotype most DBS
with a viral load ,10000 copies/mL. In DBS that yielded a genotype, there was high concordance with a
plasma-based assay.
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Introduction
By the end of 2008, .4 million people were receiving antiretro-
viral treatment (ART) of HIV/AIDS in low- and middle-income
countries, which is a 10-fold expansion over the past 5 years.
1
The probability of drug resistance increases with duration of
treatment and has been estimated to reach 27% by 6 years.
2
Thus, the number of individuals in need of second-line ART in
low- and middle-income countries can be expected to rise
sharply in the coming years.
Drug resistance testing is standard of care in industrialized
countries in order to tailor new fully active regimens in patients
with treatment failure, but is rarely available in resource-limited
settings due to high costs and stringent requirements for storage
and transport of plasma. Hence, patients with treatment failure
in such settings usually switch blindly from a non-nucleoside
reverse transcriptase inhibitor (NNRTI)-based regimen to a pro-
tease inhibitor-based regimen. However, since most patients
with treatment failure are detected late, at which stage wide-
spread resistance is common, patients risk undergoing switches
to regimens with limited efﬁcacy. Further down the line, switching
blindlytoathird-orfourth-lineregimenwillbevirtuallyimpossible
without access to resistance testing.
Dried blood spots (DBS) are easy to collect and store, and can
be a convenient alternative to plasma. Recently, several studies
have demonstrated the feasibility and reliability of using DBS to
monitor HIV drug resistance.
3–6 However, most studies utilized
in-house genotyping assays, and few used specimens collected
under ‘real-life’ ﬁeld conditions. Commercial genotyping kits
have several advantages over in-house assays, including quality-
controlled reagents, standardized protocols and validated
interpretation tools, and would facilitate routine use in
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260high-throughput settings; however, these kits have only been
validated with plasma. We therefore aimed to assess the
performance of the ViroSeq assay in conjunction with DBS
obtained under ﬁeld conditions from patients failing ART in
rural Tanzania.
Patients and methods
We utilized 36 remnant DBS cards collected from patients with known
treatment failure of an NNRTI-based ﬁrst-line regimen at Haydom
Lutheran Hospital. Median plasma viral load was 15180 copies/mL
(range 1350–3683000), and a plasma genotype was available from all
patients. HIV-1 subtypes were A (n¼11), C (n¼10), D (n¼12) and
CRF01_AE (n¼3). A more detailed description of the study population
has been published previously.
7 All patients gave written consent to par-
ticipate in the study, and the study was approved by the National Insti-
tute for Medical Research (Tanzania) and Regional Committee for
Medical Research Ethics (Norway).
DBS were prepared by spotting whole blood from a plasma prep-
aration tube (PPT; Becton Dickinson, Franklin Lakes, NJ, USA) onto a
903 ﬁlter paper card (Whatman plc, Maidstone, UK) to completely ﬁll
the circles. The cards were dried overnight (temperature range 24–
288C) and stored in zip-lock plastic bags (purchased locally) with a
silica desiccant (Elcon-Broker AS, Holmestrand, Norway). DBS were
stored at the collection site at 2208C for a median of 126 days
Table 1. Patient characteristics and efﬁciency of HIV-1 genotyping from DBS in 36 individuals failing ART in rural Tanzania
ID no.
Viral load
(copies/mL)
CD4
(cells/mm
3) Subtype
Current ART
regimen
a
Months since
starting ART
Plasma
genotype
DBS genotype
in-house assay
b
DBS genotype
ViroSeq assay
1 3683000 381 D d4T, 3TC, EFV 14.6 ++ +
2 477500 19 D d4T, 3TC, NVP 32.3 ++ +
3 434100 31 C ZDV, 3TC, EVF 42.1 ++ +
4 420000 969 C d4T, 3TC, EFV 24.0 ++ +
5 281500 214 A no (d4T, 3TC, NVP) 45.9 ++ 2
6 229000 371 C no (d4T, 3TC, EFV) 24.0 ++ +
7 154200 62 D no (d4T, 3TC, NVP) 16.7 ++ +
8 132000 223 D no (d4T, 3TC, NVP) 30.0 ++ +
9 122900 488 A no (d4T, 3TC, NVP) 9.7 ++ 2
10 120200 469 A no (d4T, 3TC, NVP) 30.0 ++ +
11 113400 432 C ZDV, 3TC, NVP 24.5 ++ +
12 81690 673 CRF01_AE d4T, 3TC, NVP 35.5 ++ +
13 76700 224 A d4T, 3TC, NVP 9.2 ++ +
14 73400 526 A no (ZDV, 3TC, NVP) 27.3 ++ +
15 44250 547 A no (d4T, 3TC, NVP) 9.2 ++ +
16 35400 302 A d4T, 3TC, NVP 19.0 ++ 2
17 20500 122 A d4T, 3TC, EFV 28.3 ++ 2
18 15600 117 C d4T, 3TC, NVP 17.8 ++ 2
19 14750 445 A d4T, 3TC, EFV 24.2 ++ +
20 12390 148 D no (d4T, 3TC, NVP) 30.9 ++ +
21 8690 162 D d4T, 3TC, NVP 49.1 ++ 2
22 5990 768 D d4T, 3TC, NVP 36.9 ++ +
23 5560 388 CRF01_AE no (ZDV, 3TC, NVP) 9.8 ++ 2
24 3965 144 D d4T, 3TC, NVP 27.3 ++ 2
25 3198 190 D no (ZDV, 3TC, EFV) 16.2 ++ +
c
26 3101 299 A d4T, 3TC, NVP 14.5 ++ 2
27 3000 223 C d4T, 3TC, NVP 28.3 ++ 2
28 2621 244 A d4T, 3TC, NVP 32.4 + 22
29 2400 271 D d4T, 3TC, NVP 31.3 ++ 2
30 2290 454 C d4T, 3TC, NVP 28.6 ++ 2
31 2260 495 C ZDV, 3TC, NVP 25.9 ++ 2
32 1980 635 D d4T, 3TC, NVP 26.5 ++ 2
33 1886 432 C d4T, 3TC, NVP 24.0 ++ 2
34 1504 354 D d4T, 3TC, NVP 30.4 ++ 2
35 1432 810 CRF01_AE d4T, 3TC, NVP 21.1 + 22
36 1349 419 C d4T, 3TC, NVP 34.7 ++ 2
d4T, stavudine; ZDV, zidovudine; 3TC, lamivudine; NVP, nevirapine; EFV, efavirenz.
aIn patients who discontinued ART, past treatment is shown in parentheses.
bResults by the use of an in-house assay have been published previously.
7
cOnly the protease region was ampliﬁed.
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JAC(range 0–203), and exposed to ambient temperature for 20 days
during transport. Before shipment, desiccants were replaced with
new ones, after allowing the DBS to equilibrate at room temperature
for a minimum of 1 h. After arrival at the reference laboratory (Hospi-
tal Carlos III, Madrid, Spain), samples were kept at 2208C until proces-
sing 1 month later.
Total nucleic acids were extracted from two circles of dried blood,
each of which holds 75–80 mL of whole blood,
8 using the NucliSENS
silica-based extraction method (bioMe ´rieux, Inc., Durham, NC, USA) as
described previously.
7 HIV-1 genotypic analysis was done using the
ViroSeq HIV-1 Genotyping System v2.0 (Abbott Molecular, Des Plains,
IL, USA) following the manufacturer’s instructions. This method ampliﬁes
the entire protease gene and approximately two-thirds of the reverse
transcriptase (RT) gene, representing 1.8 kb of HIV-1 pol. The assay is per-
formed by a single RT–PCR and has a sensitivity of detection of 2000
HIV-1-RNA copies/mL in plasma.
Genotypes obtained with DBS were compared with those obtained
with use of a plasma-based assay. Plasma was genotyped using the
ViroSeq HIV-1 Genotyping System v2.0 with inclusion of an in-house
RT-nested PCR step as previously described.
7 Resistance proﬁles to antire-
troviral drugs were interpreted according to the Stanford University HIV
Drug Resistance Database (HIVdb Program, http://hivdb.stanford.edu).
Only drug resistance mutations listed in the December 2009 update
from the International AIDS Society were considered in the present
study.
9 Logistic regression was used to study factors associated with
ampliﬁcation failure. Data were analysed with SPSS v16.0 for Windows
(SPSS Inc., Chicago, IL, USA). All tests were two-sided and the level of
signiﬁcance was set at P,0.05.
Results
HIV-1 pol was successfully ampliﬁed in 17 of 36 (47%) DBS speci-
mens using the ViroSeq assay, but one of these yielded a geno-
type in the protease region only (Table 1). Most of the
ampliﬁcation failures occurred in specimens with low-level virae-
mia. Only 2 of 16 (13%) DBS with a viral load of ,10000 copies/
mL could be ampliﬁed, compared with 15 of 20 (75%) DBS with a
viral load of .10000 copies/mL (P¼0.001). Ampliﬁcation failures
were observed with all HIV-1 subtypes in the study population: A
(n¼6); C (n¼6); D (n¼5); and CRF01_AE (n¼2). In specimens
with viral loads of .10000 copies/mL, four of ﬁve ampliﬁcation
failures were subtype A; however, numbers were small and not
statistically signiﬁcant. Furthermore, there was no signiﬁcant
association between the length of DBS storage at 2208C and
ampliﬁcation failure (P¼0.70).
Seventeen plasma/DBS pairs were available for comparison
(Table 2). Of 77 protease mutations found in plasma, 70 (91%)
were also detected in DBS, all of which were minor mutations
or polymorphisms. The seven protease mutations missed in
DBS were present in plasma as mixtures with the wild-type
strain. No additional protease mutations were observed in DBS.
In the RT region, all 23 clinically signiﬁcant mutations in
plasma were also detected in DBS. In addition, one RT mutation
was found in DBS only, as a mixture in the 101 position (K101EK
in patient 13) with some impact on etravirine resistance
Table 2. Mutations in the protease and RT genes in 17 matched plasma/DBS specimens from patients failing ART in rural Tanzania
ID
no.
Protease RT
plasma DBS plasma DBS
1 I13V, M36I, D60E, I64V I13V, M36I, D60E, I64V none none
2 I13V, K20R, M36MV, L63P, I64V,
I93IL
I13V, K20R, L63P, I64V G190A G190A
3 M36I, L63LP, H69K, I93L M36I, L63LP, H69K, I93L K103N, E138A K103N, E138A
4 M36I, L63P, H69K, I93L M36I, L63P, H69K, I93L none none
6 G16E, H69K, V77I, I93L G16E, H69K, V77I, I93L K103N, V108IV, M184V, P225H K103N, V108IV, M184V, P225H
7 I13V, K20R, M36MI, I62IV, I64V I13V, K20R, I62IV, I64V none none
8 L10IV, I13IV, G16GE, I62V, I64V,
V77I, I85IV
L10IV, G16E, I62V, I64V,
V77I
M184V, G190A M184V, G190A
10 I13V, M36I, L63P, I64V, H69K, V77I I13V, M36I, L63P, I64V,
H69K, V77I
K103KN K103KN
11 M36I, H69K, I93L M36I, H69K, I93L none none
12 I13V, M36I, L63P, H69K I13V, M36I, L63P, H69K D67N, K70R, K103N, V179TV,
M184V, K219Q
D67N, K70R, K103N, V179T,
M184V, K219Q
13 I13V, M36I, L63LP, H69K, V82VI I13V, M36I, H69K, V82IV V179T, M184V, G190A K101EK, V179T, M184V, G190A
14 I13V, M36I, H69K I13V, M36I, H69K none none
15 L10V, I13V, G16E, M36I, I62IV,
H69K
L10V, I13V, G16E, M36I,
H69K
E138A E138A
19 I13V, M36I, D60E, L63P, H69K I13V, M36I, D60E, L63P,
H69K
none none
20 L63P, V77VI L63LP, V77IV none none
22 I13V, L63P, I64V, V77I I13V, L63LP, I64V, V77I K101E, M184V, G190A K101E, M184V, G190A
25 I13V, K20R, M36I, I62IV, I64IV I13V, K20R, M36I, I62V,
I64IV
none failed
Discordances between plasma and DBS are underlined. Discordances that represent drug-resistant mutations are bold and underlined.
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262interpretation. Thus, 16 of 17 (94%) patients had identical resist-
ance proﬁles to antiretroviral drugs in plasma and DBS.
The whole sequence of 1302 bases was compared between
plasma and DBS, with mixed bases being classiﬁed as different.
Mean nucleotide similarity was 98.7% (SD 0.62), ranging from
97.5% to 99.7%.
DBS genotypes obtained with the ViroSeq assay were
highly concordant with those obtained with use of a previously
published in-house DBS method.
7 Of 94 mutations found with
the ViroSeq assay, 88 (93.6%) were also detected with the
in-house assay, and vice versa.
Discussion
The ViroSeq kit successfully genotyped approximately half of DBS
specimens from patients with ART failure in rural Tanzania.
Although efﬁcient in patients with high viral loads, the ViroSeq
kit failed to genotype most DBS specimens with viral loads of
,10000 copies/mL. In the specimens that yielded a genotype,
however, there was high concordance with results from a
plasma-based assay.
Three previous studies have assessed the ViroSeq kit in con-
junction with DBS. Masciotra et al.
4 successfully genotyped all
DBS with viral loads of .2000 copies/mL, compared with 55%
of those with viral loads of ,2000 copies/mL. Youngpairoj
et al.
5 reported that only 8% of DBS could be genotyped when
viral load was ,10000 copies/mL, compared with 81% when
viral load was .10000 copies/mL, similar to our results. Finally,
in a recent study from Mexico, Lira et al.
10 successfully geno-
typed 60% of DBS with viral loads of .14000 copies/mL, but
none of the DBS with viral loads below this level. All these
studies found high concordance between nucleotide sequences
derived from DBS and plasma, in line with our ﬁndings. Our
study, however, is the ﬁrst to assess the ViroSeq kit with DBS
from patients infected with non-B subtypes. The ViroSeq kit
was originally optimized for HIV-1 subtype B;
11 hence, future
DBS studies should aim to include various subtypes, including
subtype A, which frequently failed ampliﬁcation in our study,
even in specimens with high viral loads.
Previously, we reported 94% ampliﬁcation success from DBS
collected in duplicate with DBS utilized in the present study and
stored under less favourable conditions, using an in-house
RT-nested PCR method.
7 Youngpairoj et al.
5 reported similar
results; overall ampliﬁcation success was 57.5% with the
ViroSeq kit and 95% with an in-house nested assay. In-house
assays typically reduce the costs by .50% compared with
commercial kits.
12 Furthermore, the use of a nested PCR proto-
col appears to increase sensitivity, particularly in samples with
low-level viraemia, such as patients with early treatment
failure. However, in resource-limited settings, where the
selection of second-line antiretroviral drugs is scarce, the
WHO recommends that ﬁrst-line treatment be conserved as
long as viral load does not exceed 10000 copies/mL.
13 Thus,
the ViroSeq kit in conjunction with DBS could be an acceptable
option for resistance testing under the WHO guidelines, given
that genotyping is restricted to patients who reach the
viral load threshold for regimen switch. Nonetheless, further
reﬁnement of the ViroSeq kit with DBS is warranted in order
to increase sensitivity.
Our study was limited by a relatively small sample size. More-
over, although DBS and plasma were both genotyped using
the ViroSeq kit, the use of different ampliﬁcation methods
might have contributed to discordances between the two
specimen types. The main strength of our study was that we
used samples obtained in rural Africa, and we believe our
results reﬂect ‘real-life’ performance of DBS-based resistance
monitoring in the ﬁeld. However, temperature and humidity con-
ditions differ from place to place, and the effect of various
storage conditions should be studied in more detail.
Inconclusion,wefoundthattheViroSeqkitperformedwellusing
DBS from patients with major virological failure, but failed to geno-
type most DBS with viral loads of ,10000 copies/mL. In DBS
samples that yielded a genotype, there was high concordance
betweenmutationsfoundinDBSandplasma.UsingtheWHOguide-
lines for ART in resource-limited settings, recommending regimen
switch only in patients with viral loads of .10000 copies/mL, the
ViroSeq kit in conjunction with DBS could be an acceptable option
for drug resistance testing.
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